Zobrazeno 1 - 10
of 149
pro vyhledávání: '"David L, Cutler"'
Autor:
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-i
Externí odkaz:
https://doaj.org/article/c0df0803d9fb4cc49e7cf54109162455
Publikováno v:
JID Innovations, Vol 3, Iss 2, Pp 100170- (2023)
Tirbanibulin 1% ointment is approved for the topical treatment of actinic keratosis, applied once daily for 5 days. Three phase 1 randomized, single-center, controlled, within-subject comparison studies were conducted to evaluate the sensitization (K
Externí odkaz:
https://doaj.org/article/d204ed72a1a54b1cae02746f5eb630bc
Autor:
Jin-Bon Hong, Po-Yuan Wu, Albert Qin, Yi-Wen Huang, Kuan-Chiao Tseng, Ching-Yu Lai, Wing-Kai Chan, Jane Fang, David L. Cutler, Tsen-Fang Tsai
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2159 (2022)
Plaque-type psoriasis is a common skin disorder. Tirbanibulin (KX01) is a new Src kinase inhibitor with potent antiproliferative activity against keratinocytes and has been approved for treatment of actinic keratosis. This Phase I study investigates
Externí odkaz:
https://doaj.org/article/3bad5e6818634c3fb39be705f2a26129
Publikováno v:
Journal of Clinical Oncology. 41:1323-1324
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90cc005017e1f6a7870dedd795c92534
https://doi.org/10.1200/jco.22.02157
https://doi.org/10.1200/jco.22.02157
Autor:
Hope S, Rugo, Gerardo A, Umanzor, Francisco J, Barrios, Rosa H, Vasallo, Marco A, Chivalan, Suyapa, Bejarano, Julio R, Ramírez, Luis, Fein, Ruben D, Kowalyszyn, E Douglas, Kramer, Hui, Wang, Min-Fun R, Kwan, David L, Cutler
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(1)
PURPOSE Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f1080421c72b6cc7509f5d3d50bf43
https://pubmed.ncbi.nlm.nih.gov/35858154
https://pubmed.ncbi.nlm.nih.gov/35858154
Autor:
Andrew, Blauvelt, Steven, Kempers, Edward, Lain, Todd, Schlesinger, Stephen, Tyring, Seth, Forman, Glynis, Ablon, George, Martin, Hui, Wang, David L, Cutler, Jane, Fang, Min-Fun R, Kwan, Martin, Zaiac
Publikováno v:
New England Journal of Medicine. 384:512-520
The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, a precursor of squamous-cell carcinoma.In two identically designed double-blind trials, we randomly assigne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb8c12601dd3e9cc74fff8894dda047
https://doi.org/10.1056/nejmoa2024040
https://doi.org/10.1056/nejmoa2024040
Autor:
Haihong Shi, Vikas Kumar Dawra, Almasa Bass, Anne Hickman, Susan Zhou, Yali Liang, David L. Cutler, Steven G. Terra, Vaishali Sahasrabudhe
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective Ertugliflozin is approved in the US and European Union as a stand-alone product for adults with type 2 diabetes mellitus as once daily (QD) dosing. The approved fixed-dose combination (FDC) of ertugliflozin and immediate-release metformin i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b4984e112db0b7438a4f3bc3b713b0
https://doi.org/10.5414/cp203343
https://doi.org/10.5414/cp203343
Autor:
Anne Hickman, Susan Zhou, Didier Saur, Steven G. Terra, David L. Cutler, Vaishali Sahasrabudhe, Kyle Matschke, Sangeeta Raje, Haihong Shi
Publikováno v:
Clinical Therapeutics. 40:1701-1710
Purpose Ertugliflozin, an oral, highly selective inhibitor of the sodium-glucose cotransporter 2, is approved in the United States and the European Union for the treatment of adults with type 2 diabetes mellitus. Hepatic impairment may affect, to var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c0451a6b71bbbcb1fd31bb3a1f4123
https://doi.org/10.1016/j.clinthera.2018.06.015
https://doi.org/10.1016/j.clinthera.2018.06.015
Autor:
Vikas Kumar Dawra, Didier Saur, David L. Cutler, Anne Hickman, Steven G. Terra, Yali Liang, Vaishali Sahasrabudhe, Kyle Matschke, Haihong Shi
Publikováno v:
Clinical Therapeutics. 40:1538-1547
Purpose Ertugliflozin is a selective sodium glucose cotransporter 2 inhibitor being developed for the treatment of type 2 diabetes mellitus. The primary enzyme involved in the metabolism of ertugliflozin is uridine diphosphate-glucuronosyltransferase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01bdef95febdcaf94e60cb47c4ca455
https://doi.org/10.1016/j.clinthera.2018.07.014
https://doi.org/10.1016/j.clinthera.2018.07.014
Autor:
Johnson Y.N. Lau, Gerald J. Fetterly, Yahao Bu, Michael Smolinski, Irwin H. Gelman, Allen Barnett, Taher Hegab, David L. Cutler, David G. Hangauer, Jane W. S. Fang, Rudolf Kwan, James L. Clements
Publikováno v:
Journal of Medicinal Chemistry. 61:4704-4719
The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0cc3cb57eacb0eccb6ffc46e518704
https://doi.org/10.1021/acs.jmedchem.8b00164
https://doi.org/10.1021/acs.jmedchem.8b00164